General Information

(Note: A public offering – TiGenix has been trading on Euronext Brussels since 2007 under the symbol “TIG.”)

We are an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from our proprietary technology platforms of allogeneic, or donor-derived, stem cells. We have completed, and received positive data in, a single pivotal Phase III trial in Europe of our most advanced product candidate Cx601, a potential first-in-class injectable allogeneic stem cell therapy indicated for the treatment of complex perianal fistulas in patients suffering from Crohn’s disease. A complex perianal fistula consists of abnormal tracts between the rectum and the exterior surroundings of the anus, and is commonly associated with Crohn’s disease.

Employees: 70
Founded: 2000
Contact Information
Address Romeinse straat 12, box 2, 3001 Leuven Belgium
Phone Number +32 (16) 39 6060
Web Address http://www.tigenix.com
View Prospectus: TiGenix
Financial Information
Market Cap
Revenues $2.4 mil (last 12 months)
Net Income $-38.1 mil (last 12 months)
IPO Profile
Symbol TIG
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $57.5 mil
Manager / Joint Managers Canaccord Genuity/ KBC Securities
CO-Managers Chardan Capital Markets
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change